OSL Share Price Performance
AU$1.11
-3.69 (-76.88%)
Price AU$1.11
Share PriceAU$1.11
OSL Community Narratives
There are no narratives available yet.
Recent OSL News & Updates
No updates
OncoSil Medical Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.67
- Gross Margin
- 13.43%
- Net Profit Margin
- -659.86%
- Debt/Equity Ratio
- 0%
OncoSil Medical Limited Competitors
About OSL
- Founded
- 2005
- Employees
- n/a
- CEO
- WebsiteView website
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe. Its lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Australian Market Performance
- 7 Days: 1.1%
- 3 Months: 8.3%
- 1 Year: 14.7%
- Year to Date: 7.4%
The market has climbed 1.1% in the last 7 days, lead by the Financials sector with a gain of 1.1%. In the last year, the market has climbed 15%. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading